spacer
home > ict > summer 2019 > the landscape of clinical approval
PUBLICATIONS
International Clinical Trials

The Landscape of Clinical Approval





Cell and gene therapies, and other advanced medicinal products, have generated substantial public health interest, and deservedly so. These living drugs have shown remarkable effectiveness against cancer and other life-threatening illnesses, including rare diseases with previously no treatment available. Recent approvals of cell- and gene-based therapies underscore the industry’s conviction that these drugs will have a strong, positive impact on patient health (1-2). At the same time, accelerated approval pathways are placing a heavy onus on drug developers to assure a consistently pure and efficacious product. Sourcing donor material and assuring efficacy are a lot more complicated when a drug comprises living cells and tissues rather than synthetic products. Accelerated approval also puts significant strain on starting material suppliers, especially in the cell therapy space.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the authors


Dominic Clarke PhD has 15-plus years of experience developing enabling solutions for cell therapy and bioprocessing applications. Dominic is the Global Head of Cell Therapy at HemaCare, the leading provider of donor starting material for development and commercial cell and gene therapies, where he is actively engaged with industry experts to ensure the highest quality materials are delivered. Previously, he has held roles as the Global Product Manager for Charter Medical's cell therapy and bioprocessing disposables portfolio, focused on creating flexible closedsystem solutions for early- and late-stage production, and as the Director of Research and Development at BioLife Solutions, developing novel biopreservation media and methods to support extended stability of cells and tissues.



Brad N Taylor PhD is the Global Marketing Director at HemaCare. Brad has 13- plus years of experience in the biotech industry, addressing multiple aspects of drug discovery and preclinical development. Previously, he has held roles as Application Scientist and Product Manager in the In Vivo Imaging division of PerkinElmer, where he worked to bring innovative solutions to market to assist the research community in expediting and streamlining the process of preclinical drug discovery for cancer and other clinical applications in animal models of disease.


Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing the new Rapidox 7100

When dealing with volatile applications such as those within chemical and combustion processes, you need a high specification instrument you can trust; the Rapidox 7100 Multigas Analyser is that instrument
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

SCOPE Summit for Clinical Ops Executives

18-21 February 2020, Hyatt Regency, Orlando, Florida, US

Celebrating its 11th successful year, SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 20 different conferences, 3 plenary keynote sessions, the annual Participant Engagement Awards, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement